Tsukasa Takahashi

Tsukasa Takahashi

Auto-generated profile, based on publicly available information

Tsukasa Takahashi

Centre for Perinatal and Neonatal Medicine, Tohoku University Hospital, Sendai, Japan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
HUHaruo Usuda
Haruo Usuda
SWShimpei Watanabe
Shimpei Watanabe
MSMasatoshi Saito
Masatoshi Saito
SSShinichi Sato
Shinichi Sato
GMGabrielle C. Musk
Gabrielle C. Musk
MKMatthew W. Kemp
Matthew W. Kemp

1 February 2020 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
MKMatthew W. Kemp
Matthew W. Kemp
MSMasatoshi Saito
Masatoshi Saito
ASAugusto F Schmidt
Augusto F Schmidt
HUHaruo Usuda
Haruo Usuda
SWShimpei Watanabe
Shimpei Watanabe
AJAlan H Jobe
Alan H Jobe

1 April 2022 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Open access
TTTsukasa Takahashi
Tsukasa Takahashi
EFErin L. Fee
Erin L. Fee
YTYuki Takahashi
Yuki Takahashi
MSMasatoshi Saito
Masatoshi Saito
NYNobuo Yaegashi
Nobuo Yaegashi
MKMatthew W. Kemp
Matthew W. Kemp
Antenatal corticosteroid therapy is a standard of care for women at imminent risk of preterm labor. However, the optimal (maximum benefit and minimal risk of side effects) antenatal corticosteroid dosing strategy remains unclear. Although conveying overall benefit when given to the right patient at the right time, antenatal corticosteroid treatment efficacy is highly variable and is not risk-free. Building on earlier findings, we hypothesized that when administered in combination with slow-release betamethasone acetate, betamethasone phosphate and the high maternal-fetal betamethasone concentrations it generates are redundant for fetal lung maturation. Using an established sheep model of prematurity and postnatal ventilation of the preterm lamb, we aimed to compare the pharmacodynamic effects of low-dosage treatment with betamethasone acetate only against a standard dosage of betamethasone phosphate and betamethasone acetate as recommended by the American College of Obstetricians and Gynecologists for women at risk of imminent preterm delivery between 24 0/7 and 35 6/7 weeks' gestation. Ewes carrying a single fetus at 122±1 days' gestation (term=150 days) were randomized to receive either (1) maternal intramuscular injections of sterile saline (the saline negative control group, n=12), (2) 2 maternal intramuscular injections of 0.25 mg/kg betamethasone phosphate+betamethasone acetate administered at 24-hour dosing intervals (the betamethasone phosphate+betamethasone acetate group, n=12); or (3) 2 maternal intramuscular injections of 0.125 mg/kg betamethasone acetate administered at 24-hour dosing intervals (the betamethasone acetate group, n=11). The fetuses were surgically delivered 48 hours after treatment initiation and ventilated for 30 minutes to determine functional lung maturation. The fetuses were euthanized after ventilation, and the lungs were collected for analysis using quantitative polymerase chain reaction and Western blot assays. Fetal plasma adrenocorticotropic hormone levels were measured in the cord blood samples taken at delivery. Preterm lambs were defined as either antenatal corticosteroid treatment responders or nonresponders using an arbitrary cutoff, being a PaCO2 level at 30 minutes of ventilation being more extreme than 2 standard deviations from the mean value of the normally distributed saline control group values. Compared with the animals in the saline control group, the animals in the antenatal corticosteroid treatment groups showed significantly improved lung physiological responses (blood gas and ventilation data) and had a biochemical signature (messenger RNA and surfactant protein assays) consistent with functional maturation. However, the betamethasone acetate group had a significantly higher treatment response rate than the betamethasone phosphate+betamethasone acetate group. These physiological results were strongly correlated to the amount of surfactant protein A. Birthweight was lower in the betamethasone phosphate+betamethasone acetate group and the fetal hypothalamic-pituitary-adrenal axis was suppressed to a greater extent in the betamethasone phosphate+betamethasone acetate group. Low-dosage antenatal corticosteroid therapy solely employing betamethasone acetate was sufficient for fetal lung maturation. The elevated maternal-fetal betamethasone concentrations associated with the coadministration of betamethasone phosphate did not in addition improve lung maturation but were associated with greater fetal hypothalamic-pituitary-adrenal axis suppression, a lower antenatal corticosteroid treatment response rate, and lower birthweight-outcomes not desirable in a clinical setting. These data warranted a clinical investigation of sustained low-dosage antenatal corticosteroid treatments that avoid high maternal-fetal betamethasone exposures.

1 December 2020 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
TTTsukasa Takahashi
Tsukasa Takahashi
MSMasatoshi Saito
Masatoshi Saito
ASAugusto F. Schmidt
Augusto F. Schmidt
HUHaruo Usuda
Haruo Usuda
YTYuki Takahashi
Yuki Takahashi
MKMatthew W. Kemp
Matthew W. Kemp

1 June 2022 in American Journal of Physiology-Lung Cellular and Molecular Physiology
Verified
Journal Article
Closed access
PDF file
EFErin L. Fee
Erin L. Fee
TTTsukasa Takahashi
Tsukasa Takahashi
YTYuki Takahashi
Yuki Takahashi
SCSean Carter
Sean Carter
LFLucy Furfaro
Lucy Furfaro
MKMatthew W. Kemp
Matthew W. Kemp
Antenatal steroids (ANSs) are routinely administered to women judged to be at imminent risk of preterm delivery. Their principal benefit is precocious functional maturation of the preterm fetal lung. Current dosing regimens expose the mother and fetus to high steroid levels that may be unnecessary, increasing the potential risks of disruption to the maternal and fetal hypothalamic-pituitary-adrenal (HPA) axis and glucose regulation, alterations in placental function, and reduced fetal growth. Using a sheep model of pregnancy, we tested the hypothesis that direct fetal administration of an ultra-low dose course of betamethasone phosphate (∼0.33 mg) would be sufficient to elicit functional maturation of the fetal lung. A jugular catheter was installed in singleton ovine fetuses at 122-day gestation under general anesthesia. Animals were randomized to receive either: 1) fetal intravenous betamethasone phosphate to target fetal plasma betamethasone mean levels of 2 ng/mL for 26 h (fetal treatment group; n = 16); 2) fetal intravenous saline for 26 h and two maternal intramuscular injections of 0.25 mg/kg betamethasone phosphate + betamethasone acetate, simulating a standard clinical treatment (maternal treatment group; n = 12); or 3) fetal intravenous saline only for 26 h (negative control group; n = 10). Fetuses were delivered 48 h after surgery, ventilated for 30 min to allow the collection of lung function and physiological data, and euthanized. Quantitative PCR and Western blots were used to assess markers of lung maturation. The average total betamethasone phosphate dose for the fetal treatment group was 1% (0.3 mg) of the maternal treatment group (31-mg betamethasone phosphate + betamethasone acetate). At 30 min of ventilation, arterial PaCO2 , pH, heart rate, and ventilation efficacy index (VEI) were significantly (P < 0.05) and equivalently improved in both the fetal treatment group and maternal treatment group, relative to the negative control group. Similarly, SP-A, SP-C, and AQ-5 mRNA expression was significantly higher in both the fetal treatment group and maternal treatment group, relative to negative control. Maternal steroid administration was not required to generate preterm fetal lung maturation in sheep. Using a low dose and targeting steroid treatments directly to the fetus has the potential to significantly reduce maternal exposures, while simultaneously reducing the potential risk of adverse outcomes associated with current clinical dosing regimens.

1 November 2023 in American Journal of Physiology-Lung Cellular and Molecular Physiology
Verified
Journal Article
Closed access
EFErin L. Fee
Erin L. Fee
TTTsukasa Takahashi
Tsukasa Takahashi
YTYuki Takahashi
Yuki Takahashi
SCSean W. D. Carter
Sean W. D. Carter
MCMichael W. Clarke
Michael W. Clarke
MKMatthew W. Kemp
Matthew W. Kemp
Lung maturation benefits in preterm lambs were progressively lost when fetal plasma betamethasone concentrations fell below 2 ng/mL. The effective floor threshold for a robust, lung-maturing exposure likely lies between 1 and 2 ng betamethasone per milliliter of plasma. Hypothalamic pituitary adrenal axis signaling and immunocyte populations remained materially disrupted at subtherapeutic steroid concentrations. These data demonstrate the potential to improve antenatal steroid therapy using reduced dose regimens informed by glucocorticoid pharmacokinetics and pharmacodynamics.